Ahmed Abdelaziz, MD
Hematology & Oncology · Tucson, AZNPI 1477817971
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 62.4% of it on its own, with 59 other manufacturers making up the rest. 2025 is the largest year on record at $13,121, 6.3 times the $2,091 reported in 2019.
Across 562 payments — averaging $62.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- Medtronic$3K
- Pfizer$1K
- Novartis$929
- AstraZeneca$714
- Bristol Myers Squibb$694
- plus $6K from 54 others
Across 43 payments — averaging $21,568 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$361K
- AstraZeneca$262K
- Amgen$190K
- Genentech, Inc.$107K
- TG Therapeutics, Inc.$7K
- Janssen Research & Development, LLC$926
What the payments were for
- Speaking & faculty fees$20,11958%
- Travel & lodging$4,22712%
- Food & beverage$10,17629%
- Education$3811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMDELLTRA (AMG 757)$11,273
- VANTA ADAPTIVESTIM$1,995
- INTELLIS ADAPTIVESTIM$1,038
- Da Vinci Surgical System$192
How this compares
$34,902 in reported general payments places this provider in the 80th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 66 | $704,463 |
| CalquenceAcalabrutinib Maleate | 44 | $674,068 |
| PomalystPomalidomide | 24 | $597,989 |
| JakafiRuxolitinib Phosphate | 31 | $579,724 |
| MekinistTrametinib Dimethyl Sulfoxide | 32 | $525,967 |
| TafinlarDabrafenib Mesylate | 32 | $447,622 |
| RevlimidLenalidomide | 25 | $446,253 |
| FotivdaTivozanib Hcl | 13 | $393,241 |
| CabometyxCabozantinib S-Malate | 14 | $357,077 |
| AlecensaAlectinib Hcl | 21 | $336,877 |
| JaypircaPirtobrutinib | 14 | $324,275 |
| TagrissoOsimertinib Mesylate | 16 | $275,995 |
| Lenalidomide | 22 | $270,329 |
| LorbrenaLorlatinib | 12 | $198,271 |
| IbrancePalbociclib | 12 | $192,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMekinist, Tafinlar | $929 | $973,58964 claims |
| AstraZenecaCalquence, Tagrisso | $714 | $950,06360 claims |
| Beigene USA, Inc.Brukinsa | $55 | $704,46366 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $416 | $597,98924 claims |
| Incyte CorporationJakafi | $160 | $579,72431 claims |
| PfizerLorbrena, Ibrance, Eliquis | $1,041 | $507,541133 claims |
| Bristol Myers SquibbRevlimid | $694 | $446,25325 claims |
| Exelixis Inc.Cabometyx | $159 | $357,07714 claims |
| Array Biopharma IncBraftovi, Mektovi | $173 | $348,42222 claims |
| Genentech USA, Inc.Alecensa | $505 | $336,87721 claims |
| Lilly USA, LLCJaypirca, Olanzapine | $71 | $324,59855 claims |
| Astellas Pharma US IncXtandi | $17 | $158,45511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Tucson
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
- Alison StopeckTucson$115K
- Jaspreet ChahalTucson$104K
- Basel ShouaTucson$98K
- Akshay AmaraneniTucson$93K
- Michael BoxerTucson$30K
- Catherine AzarTucson$29K
- Ricklie JulianTucson$27K
- Sujith KalmadiChandler$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.